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Abstract 
HIV-related Kaposi sarcoma (KS) is common in sub-Saharan Africa, but optimal treatment 
strategies in resource-limited settings remain unclear. We did a retrospective cohort study of 
adults diagnosed with KS before initiating antiretroviral therapy (ART) at three ART 
programs in South Africa, Malawi and Zambia. We extracted data from medical charts at HIV 
clinics and oncological referral centers and used electronic data from the International 
epidemiology Databases to Evaluate AIDS Southern Africa. We used descriptive statistics to 
assess tumor (T) and systemic illness (S) stage and treatment of AIDS-KS patients. Kaplan-
Meier analyses were used to assess survival after KS diagnosis. We analyzed data from 57 
patients in total (20 from South Africa, 20 from Zambia, 17 from Malawi). Median age at KS 
diagnosis was 35 years and similar across sites. The percentage of patients with poor risk 
AIDS-KS (T1S1) was similar in South Africa (25%) and Malawi (24%) and higher in Zambia 
(45%). All AIDS-KS patients initiated ART at the HIV clinic. For KS care, in South Africa 18 
patients (90%) were referred to an oncology department; in Malawi and Zambia most patients 
were managed by the HIV clinics. In Malawi and South Africa, most AIDS-KS patients 
received systemic chemotherapy, in Zambia one patient received chemotherapy at the HIV 
clinic. A year after KS diagnosis, 15 patients (75%) in South Africa, 10 patients (50%) in 
Zambia, and 8 patients (47%) in Malawi were still alive; another 3 patients (15%) in South 
Africa, 8 patients (40%) in Zambia and 4 patients (24%) in Malawi were lost to follow-up. 
Management of AIDS-KS patients varied considerably across sites in Malawi, South Africa 
and Zambia. We need more reliable survival data for AIDS-KS patients in sub-Saharan Africa 
before we can assess which treatments and clinical pathways should be adopted in a specific 
setting.  
  
  
Introduction     
Kaposi sarcoma (KS) is a common HIV-related malignancy in sub-Saharan Africa (SSA) [1]. 
While HIV treatment programs have expanded massively over the past decade, resources for 
oncological care are still very limited in most SSA countries [1]. A recent Cochrane review 
[2] suggested that, in general, patients with severe HIV-related KS might benefit from a 
combination of antiretroviral therapy (ART) and chemotherapy; however, optimal 
management strategies for AIDS-KS patients in resource-limited settings remain unclear. We 
compared clinical stage, clinical management and outcomes of adult AIDS-KS patients 
enrolled in ART programs in Malawi, South Africa, and Zambia.  
  
  
Methods      
In this retrospective cohort study we included adult (aged ≥16 years) AIDS-KS patients 
diagnosed at three ART programs in South Africa, Malawi and Zambia. Ubuntu Clinic is 
located in Khayelitsha, a township outside Cape Town. Lighthouse Trust is the largest public 
ART provider in Malawi, located at the Kamuzu Central Hospital in Lilongwe. The Centre for 
Infectious Disease Research in Zambia (CIDRZ) is a non-profit organization supporting more 
than 300 public clinics; we selected three facilities in Lusaka, i.e University Teaching 
Hospital, Kalinagalinga Clinic, and Kanyama Clinic. All ART programs participate in the 
International epidemiology Databases to Evaluate AIDS Southern Africa (IeDEA-SA), and 
have local ethics committees and institutional review board approvals to contribute routine 
data for IeDEA-SA research projects. Additional approvals were obtained from the Human 
Research Ethics Committee of the University of Cape Town and the Biomedical Research 
Ethics Committee of the University of Zambia. Per ART program we aimed to include 20 
consecutive patients diagnosed with AIDS-KS before ART initiation from 2011 backwards. 
We reviewed medical charts at HIV clinics and referral oncology clinics (Groote Schuur 
Hospital, Cape Town, and Cancer Diseases Hospital, Lusaka) and retrieved data from IeDEA-
SA databases. Data was captured electronically using an online tool (REDCap). We assessed 
tumor (T) and systemic illness (S) stage according to the AIDS Clinical Trials Group (ACTG) 
system [3]. T and S stages were extracted from charts, if available, and otherwise derived 
from documented information. T0S0, T0S1 and T1S0 were considered good risk and T1S1 
poor risk. CD4 cell count at KS diagnosis was the measurement closest to KS diagnosis (-
180/+7 days). Patient and tumor characteristics at baseline and treatments received were 
analyzed descriptively. Results are presented in percentages, medians and interquartile ranges 
(IQR). We used Kaplan-Meier analyses to estimate survival after KS diagnosis. Patients were 
defined as lost to follow-up (LTFU) if there was no contact for ≥6 months prior to the data 
extraction date. Patients LTFU were censored at last contact date. In additional analyses we 
combined patients who died with those LTFU. Analyses were done in Stata 13.1 (StataCorp 
LP).  
  
  
Results      
We extracted data for 60 AIDS-KS patients. Three Malawian patients were ineligible; 57 
patients were included in the analysis. All patients were diagnosed with AIDS-KS before 
initiating ART at the HIV clinic. Two KS cases (10%) in South Africa and none in Malawi 
and Zambia were histologically confirmed. In Malawi and Zambia, most AIDS-KS patients 
were male; in South Africa, 60% (N = 12) were female (Table 1). Median age at KS 
diagnosis was 35 years (IQR 24-42 years) and similar across sites. Median CD4 cell count at 
KS diagnosis was lowest in Zambia (66 cells/µL), followed by Malawi (137 cells/µL) and 
South Africa (174 cells/µL); the percentage of missing values ranged from 10% to 44% per 
site. The percentage of patients with poor risk AIDS-KS (T1S1) was higher in Zambia (45%) 
than in South Africa (25%) and Malawi (24%). Tumors were often located on lower 
extremities (67%, N = 38) and in the oral cavity (35%, N = 20). Tumor-associated edema was 
documented in 44% of patients (N = 25). KS lesions on head/neck, trunk, and upper 
extremities were noted in most South African patients, but rarely in patients from Malawi and 
Zambia (Table 1). In Zambia, 13 patients (75%) received protease-inhibitors (PI) but none of 
the first-line ART regimens in South Africa or Malawi included PIs. In South Africa, 18 
patients (90%) were referred to an oncology department; in Malawi all treatments were 
administered at the HIV clinic. In Zambia, only one patient (5%) was referred to the oncology 
clinic but never appeared there. Most patients in South Africa and Malawi but only one 
patient in Zambia received chemotherapy (Table 1). In South Africa, all chemotherapy 
regimens given included ≥2 drugs; most commonly vincristine/bleomycin (60%, N = 12). In 
Malawi, most patients received vincristine monotherapy (65%, N = 11). Six patients from 
South Africa (30%), but none from Malawi or Zambia, received radiotherapy. The probability 
of surviving one year after KS diagnosis was 89% (95% confidence interval (CI) 62%-97%) 
in South Africa, 84% (50%-96%) in Zambia and 66% (36%-84%) in Malawi (Figure 1, 
Figure 2). When we included LTFU as a failure event, one-year survival probabilities 
dropped to 75% (95% CI 50%-89%) in South Africa, 50% (95% CI 27%-69%) in Zambia, 
and 47% (95% CI 23%-68%) in Malawi.  
  
  
Discussion      
For this international comparison, we deliberately identified patients at HIV clinics and 
followed their path through the health care system. We extracted data from charts of HIV 
clinics and oncology departments. The retrospective design ensured that we captured routine 
conditions, and that our study had no effect on clinical management. Clinical management of 
AIDS-KS patients varied across sites and countries in SSA. While South Africa offered 
combination chemotherapy at specialized oncology departments, Malawi and Zambia usually 
managed AIDS-KS patients at the ART programs. One year after KS diagnosis 75% of 
patients in South Africa and less than 50% of patients in Malawi and Zambia were alive and 
in care. Some limitations need to be addressed. Several patients were LTFU early after KS 
diagnosis, and generally, patients LTFU are more likely to have died than patients who 
remained in care [4]. To assess the impact of differential LTFU on the survival probabilities 
we performed sensitivity analyses including LTFU as a failure event. The extent of data 
recorded in medical charts varied between sites and relevant study data was often not 
available. For example, we could not assess KS response to treatment because location, 
number and extent of KS lesions were not documented in detail. In general, KS-specific 
documentation was more comprehensive in oncology departments than at HIV clinics, which 
might have caused us to underestimate clinical KS stage in patients not referred to oncology 
departments. The AIDS-KS patient load and calendar periods covered varied between sites, 
and this reduced comparability across sites. As patient populations and treatment approaches 
differ between ART programs, our findings are unlikely to be representative of all ART 
programs in Malawi, South Africa, and Zambia. Many patients were diagnosed in advanced 
AIDS-KS stage; in line with results from other studies in the region [5, 6]. In Malawi, all 
patients received chemotherapy, as described in a previous Lighthouse Trust study [7].  
  
We found that 90% of patients from Khayelitsha (Cape Town) received chemotherapy, while 
an earlier study reported that only 29% received chemotherapy [5]. This difference is likely 
due to improved service delivery over time. To our knowledge, published data on routine KS 
treatment at ART programs in Zambia are not available. Our one-year survival estimate from 
Lighthouse Trust was lower than a recent estimate from a specialized KS clinic in Malawi [6], 
perhaps because different chemotherapy regimens were used, and perhaps because more 
specialized oncological care was available at the KS clinic. Our survival estimate for South 
Africa was in line with a previous study [8]. Another study from Khayelitsha [5], which 
recruited patients earlier than we did (2001-2007 vs. 2005-2011), had shown a lower survival 
estimate at one year (60%). This might be explained by the higher proportion of patients in 
our study who received ART and chemotherapy, but also by temporal survival improvements 
in AIDS-KS patients. When ART coverage was low in SSA, most AIDS-KS patients were 
diagnosed in advanced KS stage and died a few months later. Since 2004, ART availability 
has increased substantially in Southern Africa, and efforts have been made to improve HIV 
testing and linkage to care. AIDS-KS patients should now be diagnosed in earlier KS stage. 
However, our and other studies have shown that in SAA, patients are still diagnosed in 
advanced KS stages [5,6]. In addition to HIV treatment, KS patients are likely to benefit from 
specialized oncology care. However, data from SSA are scarce and findings from high-
income countries cannot be extrapolated to African settings. Survival after KS diagnosis is an 
essential measure to assess and compare treatment outcomes in AIDS-KS patients. However, 
survival data are prone to bias if LTFU is substantial [9]. AIDS-KS patients are more likely to 
be LTFU than HIV-positive patients without KS [10], so these patients might require 
dedicated tracking efforts to obtain reliable survival estimates.  
  
  
Conclusion      
Despite increasing ART availability, many patients are still diagnosed in advanced AIDS-KS 
stage in SSA. Management of AIDS-KS patients varied considerably across sites in Malawi, 
South Africa, and Zambia, and it is unclear which treatment procedures and clinical paths 
should be adopted in which setting. Better survival data is needed to reliably assess outcomes 
across different standards of care.  
What is known about this topic 
 Kaposi sarcoma is a common HIV-related malignancy in sub-Saharan Africa;  
 Many patients in sub-Saharan Africa are diagnosed in advanced KS stages;  
 Optimal management strategies for AIDS-KS patients in resource-limited settings 
remain unclear.  
What this study adds 
 Management of AIDS-KS patients varied considerably across sites in Malawi, South 
Africa, and Zambia;  
 The majority of patients in South Africa were referred to oncology departments for KS 
care, whereas in Malawi and Zambia AIDS-KS patients were usually managed by the 
ART programs;  
 Most patients in Malawi and South Africa, but only one patient in Zambia received 
chemotherapy.  
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Table and figure      
Table 1: demographics, disease characteristics and treatment of included AIDS-KS patients  
 
Figure 1: Kaplan-Meier estimates of cumulative survival after KS diagnosis in Malawi, South 
Africa and Zambia, not including (A) and including (B) loss to follow-up as a failure event  
 
Figure 2: Kaplan-Meier estimates of cumulative survival after Kaposi sarcoma (KS) 
diagnosis in Malawi, South Africa, and Zambia, including loss to follow-up as a failure  
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Zambia, including loss to follow-up as a failure 
  
Rate this article 
 
 
Altmetric 
  
PAMJ is a member 
of the Committee 
on Publication 
Ethics 
 
PAMJ is published in collaboration with the African Field Epidemiology 
Network (AFENET) 
Currently tracked by: DOAJ, AIM, Google Scholar, AJOL, EBSCO, Scopus, 
Embase, IC, HINARI, Global Health, PubMed Central, PubMed/Medline, 
Ulrichsweb, More to come . Member of COPE.  
 
ISSN: 1937-8688. © 2018 - Pan African Medical Journal. All rights reserved  
 
